Saturday, April 20, 2024

Growth in Upstream Bioprocessing Market: Leap Driven by Biopharmaceutical Innovations and Single-Use Technologies

Similar articles

The upstream bioprocessing market is poised for exceptional growth, spurred by the biopharmaceutical industry’s continuous efforts to enhance production processes. According to an insightful report by Data Bridge Market Research, this market is projected to achieve a valuation of $14,256.78 million by the year 2029, expanding at a compound annual growth rate (CAGR) of 6.85% from 2022 to 2029.

This anticipated growth highlights the sector’s vitality and its critical contribution to the evolution of biopharmaceutical manufacturing, reflecting advancements in technology and increasing demand for biologic pharmaceuticals. The rise in the productivity of cell lines, leading to improved upstream processing efficiency, lower costs, and higher process reproducibility, is a key factor behind this market expansion.

Single-Use Technologies Revolutionize Upstream Bioprocessing Market

Innovations in cell line productivity have catalyzed improvements in upstream processing, achieving cost-effectiveness and high process reproducibility. This evolution has been significantly influenced by the transition from traditional stainless-steel bioreactors to versatile single-use technologies. The adoption of single-use systems is not merely a trend but a strategic shift aimed at enhancing manufacturing efficiency and flexibility.

Market leaders are increasingly focusing on expanding the production of single-use technologies, recognizing their growing utilization in the industry. According to Mahesh Bhalgat, Chief Operating Officer at Syngene International Limited, efforts are underway to enhance both upstream and downstream processing. Strategies include streamlining processing steps and refining growth media to maximize yields, as detailed in a Q&A session with EPR in December 2023.

Several factors contribute to the market’s robust growth. The rising incidence of chronic diseases, coupled with the enhanced efficacy of treatments, fuels the demand for high-quality biologic pharmaceuticals. Additionally, advancements in technology play a crucial role in this expansion. The development of drugs, antibody manufacturing, and the increasing research focus on cell therapy further propel the market forward.

Bioprocessing Market

Stimulating Growth in the Upstream Bioprocessing Market Through Advanced Research

Research on biosimilars, biomolecules, monoclonal antibodies, and small therapeutic peptides is also driving market advancement, reflecting a broader interest in biopharmaceutical innovation. The report emphasizes the critical need for process improvement as a key growth driver, noting the expanded consumption of processing equipment.

Driving the Upstream Bioprocessing Market’s Growth: Key Contributions from Industry Giants Thermo Fisher Scientific, Sartorius AG, Lonza, Boehringer Ingelheim International GmbH, Samsung Biologics, and AGC Biologics. These market leaders play a pivotal role in addressing the escalating demand for biopharmaceuticals, spearheading innovations to tackle global health challenges effectively.

Their efforts highlight the sector’s dedication to enhancing biopharmaceutical manufacturing processes, ensuring the development and delivery of high-quality therapeutics worldwide.

 

Resource: European Pharmaceutical Review, February 20, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article